CLEO Diagnostics LtdASX: COV

CLEO Advances Toward Clinical Validation

· Issued by CLEO Diagnostics Ltd via ASX

Filed with ASX · · 3 pages · English

Summary by 6ix AI

CLEO Diagnostics Ltd has announced the establishment of its U.S. laboratory infrastructure for Clinical Validation of its Pre-Surgical Ovarian Cancer Test, which is a key step in its FDA submission process. The Clinical Validation program will involve testing a significant number of samples across various study populations to assess the test's clinical performance. Testing is expected to begin shortly, following the receipt of test kits at the laboratory. This announcement outlines the preparations and infrastructure necessary for the final major clinical testing program supporting CLEO's regulatory pathway.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX Announcement CLEO Establishes U.S. Lab Infrastructure Ahead of Clinical Validation Highlights • CLEO has commenced preparations for Clinical Validation (CV), the ?nal major clinical testing program supporting its FDA 510(k) submission • Clinical testing infrastructure established at...

CLEO Diagnostics Ltd on 6ix

Earlier from CLEO Diagnostics

All CLEO Diagnostics news releases